File manager - Edit - /home/aussies6/mail/cur/1601327528.M187286P21748.au6.voltdns.com,S=25149,W=25738:2,
Back
Return-Path: <bounce-34353_HTML-1145078351-56268-7293150-216048@bounce.s7.exacttarget.com> Delivered-To: aussies6@au6.voltdns.com Received: from au6.voltdns.com by au6.voltdns.com with LMTP id eCOgCqhRcl/0VAAATr7HEg (envelope-from <bounce-34353_HTML-1145078351-56268-7293150-216048@bounce.s7.exacttarget.com>) for <aussies6@au6.voltdns.com>; Tue, 29 Sep 2020 07:12:08 +1000 Return-path: <bounce-34353_HTML-1145078351-56268-7293150-216048@bounce.s7.exacttarget.com> Envelope-to: ian.hamilton@aussieseafoodhouse.com.au Delivery-date: Tue, 29 Sep 2020 07:12:08 +1000 Received: from df108.mta.exacttarget.com ([13.111.2.108]:47724) by au6.voltdns.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384 (Exim 4.93) (envelope-from <bounce-34353_HTML-1145078351-56268-7293150-216048@bounce.s7.exacttarget.com>) id 1kN0RI-0005fH-S8 for ian.hamilton@aussieseafoodhouse.com.au; Tue, 29 Sep 2020 07:12:08 +1000 DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; s=200608; d=primarymarkets.com; h=Message-ID:Date:Subject:From:To:MIME-Version:Content-Type: List-Unsubscribe-Post:List-Unsubscribe:List-ID:X-CSA-Complaints; i=james.green@primarymarkets.com; bh=JqfmS0aOsd7lLZRSeJK+VfFxCp7orL0Eeg/FvsJs7aQ=; b=BrW/d/CxXjyNMbZfnCcCuUxXq6Fe4xQpkyMIzeM9wlY5s2nzR19UfKleF8mAwH0CfLHc87FyDBJY EmvJyLnmGgY8r8jviQKESJkbP9OV8Rx9NA5oTThiWRjNvMrvvZk3fg9N8nriV0piSmJpx0M62Bp7 83fqjWYMJpWuK+P7Psg= Received: by df108.mta.exacttarget.com id he98qa2fmd4s for <ian.hamilton@aussieseafoodhouse.com.au>; Mon, 28 Sep 2020 21:11:22 +0000 (envelope-from <bounce-34353_HTML-1145078351-56268-7293150-216048@bounce.s7.exacttarget.com>) X-Virus-Scanned: amavisd-new at orionsmtp-101.s7.exacttarget.com Message-ID: <fe3026f1-bfb2-405b-908f-71f3a6e0f21e@atl1s07mta3015.xt.local> Date: Mon, 28 Sep 2020 15:11:22 -0600 Subject: PrimaryMarkets Update From: James Green <james.green@primarymarkets.com> To: ian.hamilton@aussieseafoodhouse.com.au MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="_=_swift_v4_1601327337_36d38722b27c649525e563c886000af5_=_" X-Source-Ref-Id: 765662781 List-Unsubscribe-Post: List-Unsubscribe=One-Click List-Unsubscribe: <http://go.primarymarkets.com/listUnsubscribeHeader/u/279962/5dff1c304acd87442e0e3cb4b28c05bf8dda3de5195055ab75548c39ef116cbe/765662781> X-Report-Abuse-To: abuse@pd25.com X-Pardot-Route: 144:279962:765662781 List-ID: <7293150_56268.xt.local> X-CSA-Complaints: whitelistcomplaints@eco.de x-job: 7293150_56268 X-Spam-Status: No, score=0.2 X-Spam-Score: 2 X-Spam-Bar: / X-Ham-Report: Spam detection software, running on the system "au6.voltdns.com", has NOT identified this incoming email as spam. The original message has been attached to this so you can view it or label similar future email. If you have any questions, see root\@localhost for details. Content preview: Dear Ian, Today, we feature GMDx a genomics testing company that delivers the next generation of immunogenomic diagnostics in oncology. Also, outlined below are some of the benefits of raising capital via the PrimaryMarkets Platform. For more information about Capital Raising Click Here Content analysis details: (0.2 points, 5.0 required) pts rule name description ---- ---------------------- -------------------------------------------------- 0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was blocked. See http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block for more information. [URIs: primarymarkets.com] 0.1 INVESTMENT_ADVICE BODY: Message mentions investment advice -0.0 SPF_PASS SPF: sender matches SPF record 0.2 HEADER_FROM_DIFFERENT_DOMAINS From and EnvelopeFrom 2nd level mail domains are different 0.0 HTML_MESSAGE BODY: HTML included in message 0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily valid -0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from author's domain -0.1 DKIM_VALID Message has at least one valid DKIM or DK signature 0.0 LOTS_OF_MONEY Huge... sums of money X-Spam-Flag: NO --_=_swift_v4_1601327337_36d38722b27c649525e563c886000af5_=_ Content-Type: text/plain; charset=utf-8 Content-Transfer-Encoding: quoted-printable =09=09=09=20 =09=09=09=20 Dear Ian, Today, we feature GMDx a gen= omics testing company that delivers the next generation of immunogenomic di= agnostics in oncology. =09=09=09Also, outlined below are some of the b= enefits of raising capital via the PrimaryMarkets Platform. For more inform= ation about Capital Raising Click Here mailto:james.green@primarymarke= ts.com?subject=3DCapital%20Raising%20via%20the%20PrimaryMarkets%20Platform= . =09=09=09=20 =09=09=09=20 CAPITAL RAISINGS Company = Update =09=09=09An exciting business update from GMDx http://go.p= rimarymarkets.com/e/279962/assets-on-offer-gmdx-group-ltd/hzns4/765662781?h= =3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM : =09=09=09=09GMDx= has released Genomic Data Services =E2=80=9CGDS=E2=80=9D to the market in = partnership with Oracle. =09=09=09=09GMDx has achieved a very successf= ul =E2=80=98Proof of Concept=E2=80=99 for the early detection of Alzheimer= =E2=80=99s with a new Genomic Application. New patents have been lodged by = GMDx for this potential breakthrough.=20 =09=09=09=09GMDx has now entere= d into a collaboration with the CRC for Mental Heath and is working closely= with The Florey and CSIRO as part of the CRC for Mental Health. =09= =09=09=09GMDx is currently undertaking analytics on a large patient dataset= and expects to scientifically validate this genomic application in coming = weeks. =09=09=09Company Overview GMDx=20 http://go.primarymark= ets.com/e/279962/assets-on-offer-gmdx-group-ltd/hzns6/765662781?h=3DspTDqPQ= 0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM is a genomics testing company tha= t delivers the next generation of immunogenomic diagnostics in oncology. GM= Dx was established in 2015 to further develop and commercialise the discove= ries of Dr Robyn Lindley. GMDx has developed a comprehensive and powerful g= enomic-profile testing platform with the clinical applications in oncology = for:=20 =09=09=09=09predicting patient response to immunotherapy treatme= nt and =09=09=09=09predicting cancer progression. The GMDx platfo= rm technology combines proprietary predictive algorithms, a strong and exte= nsive IP portfolio, sophisticated analytics and machine learning capabiliti= es that provide customers with clinical grade whole genome testing. = =09=09=09GMDx is an Australian company raising A$1.7M, for more Information= Click Here http://go.primarymarkets.com/e/279962/assets-on-offer-gmdx= -group-ltd/hzns6/765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM= . =09=09=09For more information on raising capital via the Prima= ryMarkets Platform Click Here mailto:james.green@primarymarkets.com?su= bject=3DCapital%20Raises =09=09=09=20 =09=09=09=20 This email is= intended for Accredited/Sophisticated/Wholesale investors only. By accepti= ng this email you are self-accrediting that you so qualify. =09=09=09R= egards, =09=09=09James Green =09=09=09CEO D: +61 2 9993 4475= =20 =09=09=09W: www.primarymarkets.com http://go.primarymarkets.com= /e/279962/2020-09-28/hzns8/765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wT= glxM8ezIM | Corporate Authorised Representative: AFSL 334 838 = =09=09=09A: Level 16, 56 Pitt Street, Sydney NSW 2000, Australia =09= =09=09P: PO Box R697, Royal Exchange NSW 1225, Australia =09=09=09Conn= ect with us on: Facebook http://go.primarymarkets.com/e/279962/Primary= Markets/hznsb/765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM = | Twitter http://go.primarymarkets.com/e/279962/Primary-Markets/h= znsd/765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM | Ins= tagram http://go.primarymarkets.com/e/279962/primarymarkets-/hznsg/765= 662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM | Linkedin = http://go.primarymarkets.com/e/279962/company-primarymarkets/hznsj/76566= 2781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM =09=09=09=20 I= MPORTANT LEGAL NOTICE AND DISCLOSURES: Nothing contained in this email cons= titutes tax, legal, insurance or investment advice nor does it constitute a= solicitation or an offer to buy or sell any security or other financial in= strument. This email and any attachment(s) are intended only for the exclus= ive use of the addressee(s) and may contain information that is privileged = and confidential. If you are not the intended recipient, any use, interfere= nce with, disclosure or copying of this material is unauthorised and strict= ly prohibited. If you have received this message in error, please notify th= e sender by return email immediately and delete the message from your compu= ter without making any copies. Investing in securities in private companies= is speculative and involves a high degree of risk. The recipient must be p= repared to withstand a total loss of your investment. We strongly encourage= the recipient to complete their own independent due diligence before inves= ting in securities or financial instruments including obtaining additional = information, opinions, financial projections and legal or other investment = advice. All emails sent to or from PrimaryMarkets Limited corporate email s= ystems may be retained, monitored and/or reviewed by PrimaryMarkets and its= respective personnel. =09=09=09 Please consider the environment bef= ore printing this e-mail. =09=09=09You are receiving this email becaus= e you are a valued client or contact and we would like to keep you informed= about our platform, further updates available at www.primarymarkets.com = http://go.primarymarkets.com/e/279962/2020-09-28/hzns8/765662781?h=3DspT= DqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM - Unsubscribe http://go= .primarymarkets.com/unsubscribe/u/279962/5dff1c304acd87442e0e3cb4b28c05bf8d= da3de5195055ab75548c39ef116cbe/765662781 from email communications.= =09=09=09=20 --_=_swift_v4_1601327337_36d38722b27c649525e563c886000af5_=_ Content-Type: text/html; charset=utf-8 Content-Transfer-Encoding: quoted-printable <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.= w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"><html xmlns=3D"http://www.w3.= org/1999/xhtml" xml:lang=3D"en" lang=3D"en"><head><meta http-equiv=3D"Conte= nt-Type" content=3D"text/html;" /><title></title></head><body style=3D"font= -family: Helvetica, Arial, sans-serif; font-size: 13px"> <table border=3D= "0" cellpadding=3D"1" cellspacing=3D"1" class=3D"pd-table" style=3D"width:1= 00%;"> =09<tbody> =09=09<tr> =09=09=09<td style=3D"text-align: center= ;"><img alt=3D"" border=3D"0" height=3D"100" src=3D"https://primarymarket.w= orldsecuresystems.com/images/banners/PM%20600%20x%20100.png" style=3D"width= : 600px; height: 100px; border-width: 0px; border-style: solid;" width=3D"6= 00"></td> =09=09</tr> =09</tbody> </table> <table align=3D"cente= r" border=3D"0" cellpadding=3D"1" cellspacing=3D"1" class=3D"pd-table" styl= e=3D"width:800px;"> =09<tbody> =09=09<tr> =09=09=09<td> </td> = =09=09</tr> =09</tbody> </table> <table border=3D"0" cellpadding= =3D"1" cellspacing=3D"1" class=3D"pd-table" style=3D"width:100%;"> =09<tb= ody> =09=09<tr> =09=09=09<td style=3D"width: 217px;"> </td> =09= =09=09<td style=3D"width: 790px;"> =09=09=09<p><span style=3D"font-size:1= 3px;"><span style=3D"font-family:arial,helvetica,sans-serif;">Dear Ian,</sp= an></span></p> =09=09=09<p style=3D"font-family: Arial; font-size: 13p= x;"><span style=3D"font-family:arial,helvetica,sans-serif;">Today, we featu= re </span><strong><span style=3D"font-size:10.0pt"><span style=3D"font= -family:"Arial",sans-serif">GMDx </span></span></strong><span sty= le=3D"font-size:10.0pt"><span style=3D"font-family:"Arial",sans-s= erif">a genomics testing company that delivers the next generation of immun= ogenomic diagnostics in oncology.</span></span><br> =09=09=09<br> =09= =09=09<span style=3D"font-size:11pt"><span style=3D"font-family:Calibri,san= s-serif"><span style=3D"font-size:10.0pt"><span style=3D"font-family:"= Arial",sans-serif">Also, outlined below are some of the benefits of ra= ising capital via the PrimaryMarkets Platform. For more information about C= apital Raising <a href=3D"mailto:james.green@primarymarkets.com?subject=3DC= apital%20Raising%20via%20the%20PrimaryMarkets%20Platform"><strong><span sty= le=3D"font-family:"Arial",sans-serif"><span style=3D"color:blue">= <span style=3D"text-decoration:none"><span style=3D"text-underline:none">Cl= ick Here</span></span></span></span></strong></a>.</span></span></span></sp= an></p> =09=09=09<hr></td> =09=09=09<td style=3D"width: 214px;">&nbs= p;</td> =09=09</tr> =09</tbody> </table> <table border=3D"0" cel= lpadding=3D"1" cellspacing=3D"1" class=3D"pd-table" style=3D"width:100%;">= =09<tbody> =09=09<tr> =09=09=09<td style=3D"width: 217px;"> </t= d> =09=09=09<td style=3D"width: 790px;"> =09=09=09<div style=3D"text-al= ign: center;"><img alt=3D"" border=3D"0" height=3D"100" src=3D"https://prim= arymarket.worldsecuresystems.com/images/Logos/GMDx%20200%20x%20100.png" sty= le=3D"width: 200px; height: 100px; border-width: 0px; border-style: solid;"= width=3D"200"></div> =09=09=09<hr> =09=09=09<p style=3D"font-family= : Arial; font-size: 13px; text-align: center;"><span style=3D"color:#0000FF= ;"><u><strong><span style=3D"font-size:14px;">CAPITAL RAISINGS</span></stro= ng></u></span></p> =09=09=09<p style=3D"font-family: Arial; font-size:= 13px;"><span style=3D"font-size:11pt"><span style=3D"font-family:Calibri,s= ans-serif"><b><u><span style=3D"font-size:10.0pt"><span style=3D"font-famil= y:"Arial",sans-serif">Company Update</span></span></u></b><br> = =09=09=09<br> =09=09=09<span style=3D"font-size:10.0pt"><span style=3D"fo= nt-family:"Arial",sans-serif">An exciting business update from <a= href=3D"http://go.primarymarkets.com/e/279962/assets-on-offer-gmdx-group-l= td/hzns4/765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM" target= =3D"_blank"><strong>GMDx</strong></a>:</span></span></span></span></p> = =09=09=09<ul> =09=09=09=09<li><span style=3D"font-size:11pt"><span sty= le=3D"tab-stops:list 36.0pt"><span style=3D"font-family:Calibri,sans-serif"= ><span style=3D"font-size:10.0pt"><span style=3D"font-family:"Arial&qu= ot;,sans-serif">GMDx has released Genomic Data Services =E2=80=9CGDS= =E2=80=9D to the market in partnership with Oracle.</span></span></span></s= pan></span></li> =09=09=09=09<li><span style=3D"font-size:11pt"><span sty= le=3D"tab-stops:list 36.0pt"><span style=3D"font-family:Calibri,sans-serif"= ><span style=3D"font-size:10.0pt"><span style=3D"font-family:"Arial&qu= ot;,sans-serif">GMDx has achieved a very successful =E2=80=98Proof of Conce= pt=E2=80=99 for the early detection of Alzheimer=E2=80=99s with a new Genom= ic Application. New patents have been lodged by GMDx for this potential bre= akthrough. </span></span></span></span></span></li> =09=09=09=09<li><span= style=3D"font-size:11pt"><span style=3D"tab-stops:list 36.0pt"><span style= =3D"font-family:Calibri,sans-serif"><span style=3D"font-size:10.0pt"><span = style=3D"font-family:"Arial",sans-serif">GMDx has now entered int= o a collaboration with the CRC for Mental Heath and is working closely with= The Florey and CSIRO as part of the CRC for Mental Health.</span></span></= span></span></span></li> =09=09=09=09<li><span style=3D"font-size:11pt"><= span style=3D"tab-stops:list 36.0pt"><span style=3D"font-family:Calibri,san= s-serif"><span style=3D"font-size:10.0pt"><span style=3D"font-family:"= Arial",sans-serif">GMDx is currently undertaking analytics on a large = patient dataset and expects to scientifically validate this genomic applica= tion in coming weeks</span></span>.</span></span></span></li> =09=09=09</= ul> =09=09=09<span style=3D"font-size:11pt"><span style=3D"font-family:Ca= libri,sans-serif"><span style=3D"font-size:10.0pt"><span style=3D"font-fami= ly:"Arial",sans-serif"><strong><span style=3D"font-family:"A= rial",sans-serif"><span style=3D"text-decoration:none"><span style=3D"= text-underline:none"><u>Company Overview</u></span></span></span></strong><= /span></span></span></span> =09=09=09<p style=3D"font-family: Arial; f= ont-size: 13px;"><span style=3D"font-size:11pt"><span style=3D"font-family:= Calibri,sans-serif"><span style=3D"font-size:10.0pt"><span style=3D"font-fa= mily:"Arial",sans-serif"><a href=3D"http://go.primarymarkets.com/= e/279962/assets-on-offer-gmdx-group-ltd/hzns6/765662781?h=3DspTDqPQ0GPua5jY= n4BLnRuu09xJAHNw8wTglxM8ezIM" target=3D"_blank"><strong><span style=3D"font= -family:"Arial",sans-serif"><span style=3D"color:blue"><span styl= e=3D"text-decoration:none"><span style=3D"text-underline:none">GMDx </span>= </span></span></span></strong></a>is a genomics testing company that delive= rs the next generation of immunogenomic diagnostics in oncology. GMDx was e= stablished in 2015 to further develop and commercialise the discoveries of = Dr Robyn Lindley. GMDx has developed a comprehensive and powerful genomic-p= rofile testing platform with the clinical applications in oncology for:&n= bsp;</span></span></span></span></p> =09=09=09<ul> =09=09=09=09<li><= span style=3D"font-size:11pt"><span style=3D"tab-stops:list 36.0pt"><span s= tyle=3D"font-family:Calibri,sans-serif"><span style=3D"font-size:10.0pt"><s= pan style=3D"font-family:"Arial",sans-serif">predicting patient r= esponse to immunotherapy treatment and</span></span></span></span></span></= li> =09=09=09=09<li><span style=3D"font-size:11pt"><span style=3D"tab-sto= ps:list 36.0pt"><span style=3D"font-family:Calibri,sans-serif"><span style= =3D"font-size:10.0pt"><span style=3D"font-family:"Arial",sans-ser= if">predicting cancer progression.</span></span></span></span></span></li>= =09=09=09</ul> =09=09=09<p style=3D"font-family: Arial; font-size: = 13px;"><span style=3D"font-size:11pt"><span style=3D"font-family:Calibri,sa= ns-serif"><span style=3D"font-size:10.0pt"><span style=3D"font-family:"= ;Arial",sans-serif">The GMDx platform technology combines proprietary = predictive algorithms, a strong and extensive IP portfolio, sophisticated a= nalytics and machine learning capabilities that provide customers= with clinical grade whole genome testing.<br> =09=09=09<br> =09=09=09G= MDx is an Australian company raising A$1.7M, for more Information <a href= =3D"http://go.primarymarkets.com/e/279962/assets-on-offer-gmdx-group-ltd/hz= ns6/765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM" target=3D"_b= lank"><strong><span style=3D"font-family:"Arial",sans-serif"><spa= n style=3D"color:blue"><span style=3D"text-decoration:none"><span style=3D"= text-underline:none">Click Here</span></span></span></span></strong></a>.</= span></span></span></span></p> =09=09=09<hr> =09=09=09<div style=3D"= text-align: center;"><img alt=3D"" border=3D"0" height=3D"433" src=3D"https= ://primarymarket.worldsecuresystems.com/images/listings/2020/Capital%20Rais= e%20650%20x%20433%20(3).png" style=3D"width: 650px; height: 433px; border-w= idth: 0px; border-style: solid;" width=3D"650"><br> =09=09=09<span style= =3D"font-size:13px;"><span style=3D"font-family:Arial,Helvetica,sans-serif;= ">For more information on raising capital via the PrimaryMarkets Platform <= strong><a href=3D"mailto:james.green@primarymarkets.com?subject=3DCapital%2= 0Raises">Click Here</a></strong></span></span></div> =09=09=09<hr></td= > =09=09=09<td style=3D"width: 214px;"> </td> =09=09</tr> =09</t= body> </table> <table border=3D"0" cellpadding=3D"1" cellspacing=3D"= 1" class=3D"pd-table" style=3D"width:100%;"> =09<tbody> =09=09<tr> = =09=09=09<td style=3D"width: 166px;"> </td> =09=09=09<td style=3D"wi= dth: 653px;"> =09=09=09<p><span style=3D"font-size:13px;"><span style=3D"= font-family:arial,helvetica,sans-serif;">This email is intended for Accredi= ted/Sophisticated/Wholesale investors only. By accepting this email you are= self-accrediting that you so qualify.<br> =09=09=09<br> =09=09=09Regar= ds,</span></span><br> =09=09=09<br> =09=09=09<b>James Green</b><br> = =09=09=09<span style=3D"font-size:10px;"><span style=3D"font-family:arial,h= elvetica,sans-serif;">CEO</span></span><br> =09=09=09<img alt=3D"" border= =3D"0" height=3D"71" src=3D"https://primarymarket.worldsecuresystems.com/im= ages/Logos/PM%20216x73.png" style=3D"width: 216px; height: 71px; border-wid= th: 0px; border-style: solid;" width=3D"216"></p> =09=09=09<p style=3D= "font-family: Arial; font-size: 10px; text-align: justify;"><strong>D:</str= ong> +61 2 9993 4475 <br> =09=09=09<strong>W:</strong> <a href=3D"ht= tp://go.primarymarkets.com/e/279962/2020-09-28/hzns8/765662781?h=3DspTDqPQ0= GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM" target=3D"_blank">www.primarymarkets.c= om</a> | Corporate Authorised Representative: AFSL 334 838<br> =09=09=09<= strong>A:</strong> Level 16, 56 Pitt Street, Sydney NSW 2000, Australi= a<br> =09=09=09<strong>P:</strong> PO Box R697, Royal Exchange NSW 1= 225, Australia<br> =09=09=09<br> =09=09=09<span style=3D"font-size: 11p= x;">Connect with us on: </span><a href=3D"http://go.primarymarkets.com/e/27= 9962/PrimaryMarkets/hznsb/765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTg= lxM8ezIM" style=3D"font-size: 11px;">Facebook</a> <span style=3D"font-size:= 11px;"> | </span><a href=3D"http://go.primarymarkets.com/e/279962/Primary-= Markets/hznsd/765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM" st= yle=3D"font-size: 11px;">Twitter</a><span style=3D"font-size: 11px;"> | </s= pan> <a href=3D"http://go.primarymarkets.com/e/279962/primarymarkets-/hznsg= /765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM" style=3D"font-s= ize: 11px;">Instagram</a><span style=3D"font-size: 11px;"> | </span><a href= =3D"http://go.primarymarkets.com/e/279962/company-primarymarkets/hznsj/7656= 62781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM" style=3D"font-size: = 11px;">Linkedin</a><br> =09=09=09 </p> =09=09=09<p style=3D"fon= t-family: Arial; font-size: 10px; text-align: justify;">IMPORTANT LEGAL NOT= ICE AND DISCLOSURES: Nothing contained in this email constitutes tax, legal= , insurance or investment advice nor does it constitute a solicitation or a= n offer to buy or sell any security or other financial instrument. Thi= s email and any attachment(s) are intended only for the exclusive use of th= e addressee(s) and may contain information that is privileged and confident= ial. If you are not the intended recipient, any use, interference with, dis= closure or copying of this material is unauthorised and strictly prohibited= . If you have received this message in error, please notify the sender by r= eturn email immediately and delete the message from your computer without m= aking any copies. Investing in securities in private companies is speculati= ve and involves a high degree of risk. The recipient must be prepared to = withstand a total loss of your investment. We strongly encourage the recipi= ent to complete their own independent due diligence before investing in sec= urities or financial instruments including obtaining additional information= , opinions, financial projections and legal or other investment advice. All= emails sent to or from PrimaryMarkets Limited corporate email systems may = be retained, monitored and/or reviewed by PrimaryMarkets and its respective= personnel.<br> =09=09=09<span style=3D"font-size:9px;"> </span><spa= n><img height=3D"15" src=3D"http://primarymarket.worldsecuresystems.com/ima= ges/ss-environment.jpg" style=3D"font-size: 9px;" width=3D"15"><span style= =3D"font-size: 9px;"> </span> <strong style=3D"font-size: 9px;"><stron= g><em><span>Please consider the environment before printing this e-mail.</s= pan></em></strong></strong></span><br> =09=09=09<br> =09=09=09You are r= eceiving this email because you are a valued client or contact and we would= like to keep you informed about our platform, further updates available<em= > at <a href=3D"http://go.primarymarkets.com/e/279962/2020-09-28/hzns8= /765662781?h=3DspTDqPQ0GPua5jYn4BLnRuu09xJAHNw8wTglxM8ezIM">www.primarymark= ets.com</a> - <a href=3D"http://go.primarymarkets.com/unsubscribe= /u/279962/5dff1c304acd87442e0e3cb4b28c05bf8dda3de5195055ab75548c39ef116cbe/= 765662781">Unsubscribe</a> from email communications.</em></p> =09=09=09<= /td> =09=09=09<td style=3D"width: 215px;"> </td> =09=09</tr> =09= </tbody> </table> <img alt=3D"" src=3D"http://go.primarymarkets.com/r/2= 79962/1/765662781/open/1" /></body></html> --_=_swift_v4_1601327337_36d38722b27c649525e563c886000af5_=_--
| ver. 1.4 |
Github
|
.
| PHP 7.4.33 | Generation time: 0 |
proxy
|
phpinfo
|
Settings